India unveils first-ever national framework to tackle childhood diabetes

New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system

MSN Laboratories launches SEMABEST, India-made semaglutide pen at nearly 50% lower price

CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing

Dabur reports steady domestic growth amid global headwinds in Q4 FY26

The India FMCG business showed a sequential recovery and is expected to post high-single digit growth

Dr Jitendra Singh calls for India-led biosimilar insulin scale-up amid global supply concerns

Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation

Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes

The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology

India gets first real-time GLP-1 therapy monitoring platform

As Tracky launches integrated health solution

Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes

The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India

DrStore partners with TatvaCare to revolutionize diabetes & metabolic care in India

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan

Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema